A Phase I/II open label multicenter study of the safety and efficacy of LAG525 single agent in combination with PDR001 adminitered to patients
Clinical Trial Grant
Awarded By
Novartis Pharmaceuticals Corporation
Start Date
April 13, 2015
End Date
July 7, 2021
Awarded By
Novartis Pharmaceuticals Corporation
Start Date
April 13, 2015
End Date
July 7, 2021